PETA joins preclinical CROs at SOT to promote animal testing alternatives

By Gareth Macdonald contact

- Last updated on GMT

San Diego plays host to SOT, CROs and PETA
San Diego plays host to SOT, CROs and PETA

Related tags: Animal rights, Animal testing, Animal liberation front

Testing the toxicity of drug candidates in animals is archaic and unreliable according to PETA, which joined preclinical CROs at SOT to put forward alternatives.

The animal rights group attended the Society of Toxicology (SOT) annual conference in San Diego, US this week led by science advisor Amy Clippinger who told Outsourcing-pharma.com the idea is to track developments in the sector and to present research.

Participating in SOT's annual meeting gives us a forum to make sure we stay on top of the most cutting edge approaches that some companies are developing to replace, reduce or refine the use of animals in experiments.”

 “We present our own original research and information on the work we do to ensure that these strategies to minimize animal use are approved for use by the appropriate agencies, and also that they are put into use as widely as possible once they’ve been approved​.”

Testing drugs and vaccines​ on animals is a legal requirement in the US and EU, although companies are free to develop alternatives according to PETA research associate, Jeff Brown.

Laws on the books today require the use of animal experiments before a drug can be marketed. Government requirements vary from country to country, but no drug has yet been approved without animal testing to date​.”

Alternatives

But that does not mean there is not a desire for alternatives according to Brown, who said: “Many companies are already using innovative non-animal methods in place of animal-based experiments that were previously the only available option​.”

PETA was not the only group at SOT advocating for alternatives to animal testing.  

Chris Corsbie from Battelle Life Sciences Research told us this week that his firm monitors alternatives to keep pace with the changing environment.

He said the Battelle is "proficient in robust in vitro models for drug safety and then predicting when these new techniques will become acceptable and embraced by the FDA” adding that “the firm a goal of minimizing the use of animals in research.”

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q² Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Related suppliers

Follow us

Products

View more

Webinars